



Capnia to Present at 2016 Marcum MicroCap Conference

May 25, 2016

REDWOOD CITY, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 2016 Marcum MicroCap Conference on Wednesday, June 1, 2016 at 11:30 AM ET at the Grand Hyatt in New York City.

The presentation will be webcast live and may be accessed by visiting the "Events & Presentations" section of the Company's website at www.capnia.com. The webcast will also be available on the Company's website for a limited period of time following the conference.

About Capnia

Capnia, Inc. is a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs. Capnia's lead commercial product, CoSense End-Tidal Carbon Monoxide Monitor is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. The Company's commercial, neonatology-focused product line also includes innovative pulmonary resuscitation solutions, including the NeoPIP™ Infant T-Piece Resuscitator and Universal T-Piece Circuit consumables. Serenz Allergy Relief is Capnia's proprietary commercial product that uses nasal, non-inhaled CO₂ to relieve nasal allergy symptoms such as congestion, sneezing, itchy and runny nose. The nasal, non-inhaled CO₂ therapeutic technology is also being evaluated to treat trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia, and migraine.

Investor Relations Contact:
Michelle Carroll/Susie Kim
Argot Partners
(212) 600-1902
michelle@argotpartners.com
susan@argotpartners.com

 [Primary Logo](#)

Capnia, Inc.